ClinVar Miner

Submissions for variant NM_014141.6(CNTNAP2):c.2492C>A (p.Thr831Asn)

dbSNP: rs138344590
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV001225866 SCV001398160 uncertain significance Cortical dysplasia-focal epilepsy syndrome 2021-08-30 criteria provided, single submitter clinical testing This sequence change replaces threonine with asparagine at codon 831 of the CNTNAP2 protein (p.Thr831Asn). The threonine residue is weakly conserved and there is a small physicochemical difference between threonine and asparagine. This variant is present in population databases (rs138344590, ExAC 0.003%). This variant has not been reported in the literature in individuals affected with CNTNAP2-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
GeneDx RCV002284475 SCV002574623 uncertain significance not provided 2022-09-07 criteria provided, single submitter clinical testing Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge
Ambry Genetics RCV002429959 SCV002740885 uncertain significance Inborn genetic diseases 2017-11-17 criteria provided, single submitter clinical testing The p.T831N variant (also known as c.2492C>A), located in coding exon 16 of the CNTNAP2 gene, results from a C to A substitution at nucleotide position 2492. The threonine at codon 831 is replaced by asparagine, an amino acid with similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.